Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

Clinical development of new anticancer drugs can be compromised by a lack of qualified biomarkers. An indispensable component to successful biomarker qualification is assay validation, which is also a regulatory requirement. In order to foster flexible yet rigorous biomarker method validation, the fit-for-purpose approach has recently been developed. This minireview focuses on many of the basic issues surrounding validation of biomarker assays utilised in clinical trials. It also provides an overview on strategies to validate each of the five categories that define the majority of biomarker assays.

[1]  Anthony J. DeStefano,et al.  Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations , 2009, The AAPS Journal.

[2]  Caroline Dive,et al.  Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy , 2010 .

[3]  Binodh DeSilva,et al.  Key elements of bioanalytical method validation for macromolecules , 2007, The AAPS Journal.

[4]  Eric Woolf,et al.  Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples , 2007, The AAPS Journal.

[5]  J. W. Findlay,et al.  Specificity and Accuracy Data for Ligand-binding Assays for Macromolecules Should be Interpreted with Caution , 2008, The AAPS Journal.

[6]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[7]  P. Workman,et al.  Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development , 2009, Cancer journal.

[8]  H. Soares,et al.  Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report , 2005, Pharmaceutical Research.

[9]  Daniel Figeys,et al.  Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. , 2007, Advances in cancer research.

[10]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[11]  P. Hubert,et al.  Using tolerance intervals in pre-study validation of analytical methods to predict in-study results. The fit-for-future-purpose concept. , 2007, Journal of chromatography. A.

[12]  Stephen J. Morris,et al.  Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J Cummings,et al.  Biomarker method validation in anticancer drug development , 2008, British journal of pharmacology.

[14]  P. Workman,et al.  Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? , 2010, Drug discovery today.

[15]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[16]  M. Ranson,et al.  Optimisation of circulating biomarkers of cell death for routine clinical use. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Lisa M. McShane,et al.  Effective Incorporation of Biomarkers into Phase II Trials , 2009, Clinical Cancer Research.

[18]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[19]  Dushyant V. Sahani,et al.  Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.

[20]  J. W. Findlay,et al.  Some important considerations for validation of ligand-binding assays. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  Vinod P. Shah,et al.  Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays , 2007 .

[22]  Paul Workman,et al.  Pharmacodynamic biomarkers for molecular cancer therapeutics. , 2007, Advances in cancer research.

[23]  Serge Rudaz,et al.  A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[24]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[25]  J. W. Findlay,et al.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. , 2000, Journal of pharmaceutical and biomedical analysis.

[26]  Max Feinberg,et al.  Validation of analytical methods based on accuracy profiles. , 2007, Journal of chromatography. A.

[27]  M. Ranson,et al.  Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma , 2007, Cancer Chemotherapy and Pharmacology.

[28]  A Yacobi,et al.  Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies , 1991, European Journal of Drug Metabolism and Pharmacokinetics.

[29]  Philippe Hubert,et al.  New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data , 2004, Analytical and bioanalytical chemistry.

[30]  P. Chiap,et al.  An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progress and limitations. , 2003, Journal of pharmaceutical and biomedical analysis.